Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 16 , ISSUE 3 ( May-June, 2024 ) > List of Articles


Magnesium Sulphate Prophylaxis in Severe Preeclampsia-lessons Learnt from Recent Trials Conducted in Low-Middle-Income-Countries: A Systematic Review

Sanjoy Kumar Bhattacharyya, Dipnarayan Sarkar, Subhadeep Basak, Rumina Bagchi, Prithwikar Mandal, Alapan Halder

Keywords : Eclampsia, Low dose, Magnesium sulphate, Preeclampsia, Prophylaxis

Citation Information : Bhattacharyya SK, Sarkar D, Basak S, Bagchi R, Mandal P, Halder A. Magnesium Sulphate Prophylaxis in Severe Preeclampsia-lessons Learnt from Recent Trials Conducted in Low-Middle-Income-Countries: A Systematic Review. J South Asian Feder Obs Gynae 2024; 16 (3):258-269.

DOI: 10.5005/jp-journals-10006-2383

License: CC BY-NC 4.0

Published Online: 29-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Aim and background: Searching is ongoing to find an alternative prophylactic magnesium sulphate regimen for severe preeclampsia despite 24 hours recommendation of the World Health Organization (WHO). This review finds the provision of any such substitute prophylactic instead of the recommended ones searching through the recently published trials. Objectives: To endorse any alternative prophylactic magnesium sulphate regimen effective for severe preeclampsia. Methods: Data sources: Studies are retrieved from the bibliographic databases of PubMed, Scopus, and Cochrane Library. Eligibility Criteria, Participants, and Interventions: Included studies are recently published trials intended to compare the efficacy of different modified regimens of magnesium sulphate prophylaxis for women with severe preeclampsia in contrast to the standard regimen. Results: Out of a total of fifteen, eight studies evaluated different abbreviated regimens of magnesium sulphate prophylaxis. A lower maintenance dose of magnesium sulphate as preeclampsia-prophylaxis was assessed by two. In addition, four studies evaluated the efficacy of only loading doses of magnesium sulphate as prophylaxis. Finally, one study estimated a placebo in the postpartum period compared to the standard regimen. No incidence of eclampsia was reported in any group of eight studies. Even in the rest seven studies, eclampsia incidences did not appear significantly higher in the study group allocated for either abbreviated or low dose or loading-dose regimens. However, a statistically significant number of women in the study groups needed extension/reinstitution of prophylaxis. Low-dose and loading dose prophylaxis are found unsuitable for a recommendation. Apart from the established safety potential, abbreviated/short-course prophylaxes of magnesium sulphate have been found to generate different secondary benefits. Conclusions: The abbreviated postpartum regimen of magnesium sulphate can be recommended as prophylaxis for severe preeclampsia instead of recommended schedule if applied judicially.

PDF Share
  1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: A WHO systematic analysis. Lancet Global Health 2014;2(6): e323–e333. DOI: 10.1016/S2214-109X(14)70227-X.
  2. Khedagi AM, Bello NA. Hypertensive Disorders of Pregnancy. Cardiol Clin 2021;39(1):77–90. DOI: 10.1016/j.ccl.2020.09.005.
  3. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol 2020;135(6):e237–e260. DOI: 10.1097/AOG.0000000000003891.
  4. Nada Hamadeh, Catherine Van Rompey, Eric Metreau, et al. New World Bank country classifications by income level: 2021–2022. World Bank; 2021. Available from:
  5. Von Dadelszen P, Magee LA, Devarakonda RM, et al. The prediction of adverse maternal outcomes in preeclampsia. J Obstet Gynaecol Can 2004;26(10):871–879. DOI: 10.1016/s1701-2163(16)30137-2.
  6. Cunningham F, Leveno KJ, Bloom SL, (Eds). Hypertensive disorders. Williams Obstetrics: McGraw-Hill Education; 2018. pp. 25e. Available from:§ionid=169756263.
  7. Duley L. The global impact of preeclampsia and eclampsia. Semin Perinatol 2009;33(3):130–137. DOI: 10.1053/j.semperi.2009.02.010.
  8. Espinoza J. Recent biomarkers for the identification of patients at risk for preeclampsia: The role of uteroplacental ischemia. Expert Opin Med Diagn 2012;6(2):121–130. DOI: 10.1517/17530059.2012. 659726.
  9. Duley L, Gulmezoglu AM, Henderson-Smart DJ, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2000;(11):CD000025. DOI:
  10. WHO Reproductive Health Library. WHO recommendation on magnesium sulfate for the prevention of eclampsia in women with severe pre-eclampsia. The WHO Reproductive Health Library; Geneva: World Health Organization; 2021.
  11. Van Laecke S. Hypomagnesemia and hypermagnesemia. Acta Clin Belg 2019;74(1):41–47. DOI:
  12. Ritchie LMP, Khan S, Moore JE, et al. Low- and middle-income countries face many common barriers to implementation of maternal health evidence products. Journal of Clinical Epidemiology 2016;76:229–237. DOI:
  13. Cahill AG, Macones GA, Odibo AO, et al. Magnesium for seizure prophylaxis in patients with mild preeclampsia. Obstet Gynecol 2007;110(3):601–607. DOI: 10.1097/01.AOG.0000279152. 66491.78.
  14. Duley L, Matar HE, Almerie MQ, et al. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2010;2010(8):CD007388. DOI: 10.1002/14651858.CD007388.pub2.
  15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 2009;62(10):e1–34. DOI: 10.1016/j.jclinepi.2009. 06.006.
  16. Medical Subject Heading Home provided by National Library of Medicine, National Institutes of Health (U.S.) Medical Subject Headings. Available from:
  17. Higgins JP, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.1. Cochrane, 2020. Available from:
  18. Vigil-De Gracia P, Ramirez R, Durán Y, et al. Magnesium sulfate for 6 vs 24 hours post-delivery in patients who received magnesium sulfate for less than 8 hours before birth: A randomized clinical trial. BMC Pregnancy Childbirth 2017;17(1):241. DOI:
  19. Unwaha EA, Bello FA, Bello OO, et al. Intravenous magnesium sulfate in the management of severe pre-eclampsia: A randomized study of 12-hour versus 24-hour maintenance dose. Int J Gynaecol Obstet 2019;149(1):37–42. DOI:
  20. Anjum S, Rajaram GP, Bano I. Short-course postpartum (6-h) magnesium sulfate therapy in severe preeclampsia. Arch Gynecol Obstet 2016;293(5):983–986. DOI: 10.1007/s00404-015-3903-y.
  21. Darngawn L, Jose R, Regi A, et al. A shortened postpartum magnesium sulfate prophylaxis regime in pre-eclamptic women at low risk of eclampsia. Int J Gynaecol Obstet 2012;116(3):237–239. DOI: 10.1016/j.ijgo.2011.09.028.
  22. Maia SB, Katz L, Neto CN, et al. Abbreviated (12-hour) versus traditional (24-hour) postpartum magnesium sulfate therapy in severe pre-eclampsia. Int J Gynaecol Obstet 2014;126(3):260–264. DOI: 10.1016/j.ijgo.2014.03.024.
  23. Orisabinone IB, Onwudiegwu U, Adeyemi AB, et al. Shortened versus standard post-partum maintenance therapy of magnesium sulphate in severe pre-eclampsia: A randomised control trial. Int J Reprod Contracept Obstet Gynecol 2020;9(4):1646–1653. DOI:
  24. Leal NV, Amorim MM, Franca-Neto AH, et al. 12-hour compared with 24-hour postpartum magnesium sulfate therapy in preeclampsia: A randomized clinical trial. Obstet Gynecol 2014;123(Suppl 1):64S. DOI: 10.1097/01.AOG.0000447370.59285.a5.
  25. Kashanian M, Koohpayehzadeh J, Sheikhansari N, et al. A comparison between the two methods of magnesium sulfate administration for duration of 12 versus 24 hours after delivery in patients with severe preeclampsia. J Matern Fetal Neonat Med 2016;29(14):2282–2287. DOI: 10.3109/14767058.2015.1083547.
  26. Pascoal ACF, Katz L, Pinto MH, et al. Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: A randomized clinical trial. Medicine (Baltimore) 2019;98(32):e16779. DOI: 10.1097/MD.0000000000016779.
  27. Charoenvidhya D, Manotaya S. Magnesium sulfate maintenance infusion in women with preeclampsia: A randomized comparison between 2 gram per hour and 1 gram per hour. J Med Assoc Thai 2013;96(4):395–398. PMID: 23691692.
  28. Shohaib T, Khan S, Javed I, et al. Loading dose of magnesium sulfate versus standard regime for prophylaxis of pre-eclampsia. J Coll Physicians Surg Pak 2009;19(1):30–33. PMID: 19149977.
  29. Rimal S, Rijal P, Bhatt R, et al. Loading dose only versus standard dose magnesium sulfate seizure prophylaxis in severe pre-eclamptic women. J Nepal Med Assoc 2017;56(208):388–394. PMID: 29453467.
  30. Keepanasseril A, Maurya DK, Manikandan K, et al. Prophylactic magnesium sulphate in prevention of eclampsia in women with severe preeclampsia: Randomised controlled trial (PIPES trial). Journal of obstetrics and gynaecology 2017;38(3):1–5. DOI:
  31. Ranganna H, Saha SC, Thami MR, et al. Prophylactic magnesium sulfate in severe preeclampsia loading—dose only vs. conventional 24 hour therapy of modified Pritchard's regime—A randomized trial. IOSR J Pharm 2014;4(6):39–47. DOI: 10.9790/3013-040602 039047.
  32. Vigil-DeGracia P, Ludmir J, Ng J, et al. Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study. BJOG 2018;125(10):1304–1311. DOI: 10.1111/1471-0528.15320.
  33. The Magpie trial. Collaboration Group. Do women with preeclampsia and their babies benefit from magnesium sulphate? The magpie trial: Arandomized placebo controlled trial. Lancet 2002;359(9321): 1877–1890. DOI:
  34. Belfort MA, Anthony J, Saade GR, et al. A comparison of magnesium sulphate and nimodipine for prevention of eclampsia. N Engl Med 2003;348(4):304–311. DOI: 10.1056/NEJMoa021180.
  35. Sibai B. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol 2004;190(6): 1520–1526. DOI: 10.1016/j.ajog.2003.12.057.
  36. Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia. Clin Pharmacokinets 2000;38:305–314. DOI:
  37. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990;163(3):1049–1055. DOI: 10.1016/0002-9378(90)91123-t.
  38. Pritchard JA, Cunningham FG, Pritchard SA. The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 cases. Am J Obstet Gynecol 1984;148(7):951–963. DOI: 10.1016/0002-9378(84)90538-6.
  39. BO Okusanya, OT Oladapo, Q Long, et al. Clinical pharmacokinetic properties of magnesium sulphate in women with pre-eclampsia and eclampsia. BJOG 2016;123(3):356–366. DOI: 10.1111/1471-0528.13753.
  40. Idama TO, Lindow SW. Magnesium sulphate: A review of clinical pharmacology applied to obstetrics. Br J Obstet Gynaecol 1998 105(3): 260–268. DOI: 10.1111/j.1471-0528.1998.tb10084.x.
  41. Begum MR, Begum A, Quadir E. Loading dose versus standard regimen of magnesium sulfate in the management of eclampsia: A randomized trial. J Obstet Gynaecol Res 2002;28(3):154–159. DOI: 10.1046/j.1341-8076.2002.00029.x.
  42. Suyajna D J, Cm V. “Single dose MgSO4 regimen” for eclampsia–A Safe Motherhood Initiative. J Clin Diagn Res 2013;7(5):868–872. DOI: 10.7860/JCDR/2013/5398.2961.
  43. Chowdhury JR, Chaudhuri S, Bhattacharyya N, et al. Comparison of intramuscular magnesium sulfate with low dose intravenous magnesium sulphate regimen for treatment of eclampsia. J Obstet Gynaecol Res 2009;35(1):119–125. DOI: 10.1111/j.1447-0756.2008.00842.x.
  44. Pratt JJ, Niedle PS, Vogel JP, et al. Alternative regimens of magnesium sulfate for treatment of preeclampsia and eclampsia: A systematic review of nonrandomized studies. Acta Obstet Gynecol Scand 2016;95(2):144–156. DOI: 10.1111/aogs.12807.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.